FDA Advisers Endorse Subcutaneous ICD

The company has proposed a postmarketing study, a prospective multicenter observational registry to evaluate the long-term safety of the device.

The FDA usually follows the recommendations of its advisory panels. Panelists have been cleared of potential conflicts of interest related to the topic of the meeting. Occasionally, a panelist may be given a waiver, but not at this meeting.